Plus   Neg

Acorda Therapeutics Inc. (ACOR) Broke Out To A New High On Study Results

Acorda Therapeutics Inc. (ACOR) announced Monday morning that data from a Phase 2 study of AMPYRA Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.

Acorda Therapeutics gapped up and rose sharply during the first 45 minutes of trade Monday, before settling into a range. The stock closed up by 3.98 at $35.50 on strong volume and broke out to a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT